2022
Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study
Tamborlane WV, Laffel LM, Shehadeh N, Isganaitis E, Van Name M, Ratnayake J, Karlsson C, Norjavaara E. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. The Lancet Diabetes & Endocrinology 2022, 10: 341-350. PMID: 35378069, PMCID: PMC10851108, DOI: 10.1016/s2213-8587(22)00052-3.Peer-Reviewed Original ResearchConceptsType 2 diabetesPlacebo-assigned participantsPrespecified sensitivity analysisSafety of dapagliflozinPhase 3 studyBetween-group differencesAdverse eventsPrimary outcomeProtocol populationTreat analysisYoung adultsWeek double-blind periodRandomised phase 3 studyDouble-blind periodSerious adverse eventsNew safety signalsOral dapagliflozinDiabetic ketoacidosisSevere hypoglycaemiaMean ageTreatment optionsCare treatmentParallel groupSafety signalsStudy personnel
2020
Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control
Van Name MA, Cheng P, Gal RL, Kollman C, Lynch J, Nelson B, Tamborlane WV, Consortium F. Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control. Diabetic Medicine 2020, 37: 863-867. PMID: 31943374, DOI: 10.1111/dme.14233.Peer-Reviewed Original ResearchConceptsType 2 diabetesType 1 diabetesPediatric Diabetes ConsortiumTarget HbAType 1Median C-peptide levelsResidual endogenous insulin secretionType 2 diabetes mellitusC-peptide levelsEndogenous insulin secretionOverweight/obeseYears of agePoor diabetes outcomesSubset of participantsCharacteristics of childrenDiabetic ketoacidosisGlycaemic controlClinical characteristicsDiabetes mellitusDiabetes outcomesRisk factorsFamilies of childrenInsulin secretionInsulin treatmentDiabetes diagnosis
2019
Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy
Siebel S, Galderisi A, Patel NS, Carria LR, Tamborlane WV, Sherr JL. Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy. Diabetes Technology & Therapeutics 2019, 21: 101-104. PMID: 30688521, PMCID: PMC6434586, DOI: 10.1089/dia.2018.0356.Peer-Reviewed Original ResearchConceptsType 1 diabetesFree fatty acidsSGLT2i useAspart insulinSGLT2 inhibitor therapyPlasma glucose levelsSodium-glucose cotransporterCanagliflozin treatmentEuglycemic DKARescue therapyBasal insulinInhibitor therapyRate of ketogenesisRescue treatmentBlunted increaseSubcutaneous injectionGlucose levelsTreatment studiesNormal increaseInsulinDiabetesTherapyKetogenesisFatty acidsTreatment
2017
Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes
Galderisi A, Sherr J, VanName M, Carria L, Zgorski M, Tichy E, Weyman K, Cengiz E, Weinzimer S, Tamborlane W. Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes. The Journal Of Clinical Endocrinology & Metabolism 2017, 103: 1088-1094. PMID: 29211871, PMCID: PMC6276715, DOI: 10.1210/jc.2017-02265.Peer-Reviewed Original ResearchConceptsMixed meal tolerance testPlasma glucagon responseWeeks of treatmentGlucagon responsePostprandial hyperglycemiaMeal-stimulated increaseWeeks of therapyPlasma glucagon levelsType 1 diabetesPlasma glucose curveBolus insulin administrationMixed meal feedingDl/minGlucagon curveAdjunctive treatmentGlucagon levelsPlasma glucagonTolerance testIncremental areaInsulin administrationGlucose curvePostmeal hyperglycemiaLiraglutideGlucose responsePretreatment responsesContinuous Glucose Monitoring in Very Preterm Infants: A Randomized Controlled Trial
Galderisi A, Facchinetti A, Steil GM, Ortiz-Rubio P, Cavallin F, Tamborlane WV, Baraldi E, Cobelli C, Trevisanuto D. Continuous Glucose Monitoring in Very Preterm Infants: A Randomized Controlled Trial. Pediatrics 2017, 140: e20171162. PMID: 28916591, DOI: 10.1542/peds.2017-1162.Peer-Reviewed Original ResearchConceptsVery preterm infantsGlucose infusion rateContinuous glucose monitoringPreterm infantsCGM groupPercentage of timeEuglycemic rangeSevere hyperglycemiaSevere hypoglycemiaGlycemic variabilityGlucose monitoringCare blood glucose monitoringUse of CGMPoor neurologic outcomeImpaired glucose controlBlood glucose monitoringBlood glucose determinationNeurologic outcomeSecondary outcomesInsulin titrationPrimary outcomeWeeks' gestationControlled TrialsGlucose controlBirth weightGlucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes
Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, Lee SW, Kaufman FR. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2017, 19: 155-163. PMID: 28134564, PMCID: PMC5359676, DOI: 10.1089/dia.2016.0421.Peer-Reviewed Original ResearchConceptsHybrid closed-loop insulin delivery systemGlucose valuesDiabetic ketoacidosis eventsMulticenter pivotal trialStudy phaseBlood sample testingType 1 diabetesClosed-loop insulin delivery systemBlood glucose valuesHome useContinuous glucose monitoringSensor glucose valuesHCl therapyKetoacidosis eventsHybrid closed-loop systemPivotal trialsInsulin delivery systemsGlucose outcomesMedtronic MiniMedType 1Glucose monitoringInsulin deliveryAdultsStayAdolescents
2016
Psychosocial predictors and moderators of weight management programme outcomes in ethnically diverse obese youth
Taylor JH, Xu Y, Li F, Shaw M, Dziura J, Caprio S, Tamborlane WV, Nowicka P, Savoye M. Psychosocial predictors and moderators of weight management programme outcomes in ethnically diverse obese youth. Pediatric Obesity 2016, 12: 453-461. PMID: 27384496, PMCID: PMC5568975, DOI: 10.1111/ijpo.12165.Peer-Reviewed Original ResearchConceptsClinic careObese youthOutpatient clinic careAbnormal glucose toleranceObesity treatment outcomesObesity intervention programFamily functioningLifestyle interventionGlucose toleranceChildhood obesityLifestyle programTreatment outcomesPsychosocial predictorsIdentification of factorsIntervention programsIntervention outcomesOutcomesPoor family functioningTreatment effectsHigh anxietyBaselineCareMonthsIntervention
2015
Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial
Libman IM, Miller KM, DiMeglio LA, Bethin KE, Katz ML, Shah A, Simmons JH, Haller MJ, Raman S, Tamborlane WV, Coffey JK, Saenz AM, Beck RW, Nadeau KJ. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. JAMA 2015, 314: 2241-2250. PMID: 26624824, DOI: 10.1001/jama.2015.16174.Peer-Reviewed Original ResearchConceptsType 1 diabetesBody mass indexGastrointestinal adverse eventsEffect of metforminTotal daily insulinGlycemic controlPlacebo groupOverweight adolescentsMetformin groupBaseline HbA1cAdverse eventsDaily insulinClinical trialsMultiple secondary end pointsOverweight/obese adolescentsSafety of metforminSecondary end pointsUse of metforminAddition of metforminBMI z-scoreMeasures of adipositySecondary outcomesBlood pressureInsulin dosePrimary outcomePresentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY study
Kelsey MM, Geffner ME, Guandalini C, Pyle L, Tamborlane WV, Zeitler PS, White NH, Group F. Presentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY study. Pediatric Diabetes 2015, 17: 212-221. PMID: 25690268, PMCID: PMC4539288, DOI: 10.1111/pedi.12264.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentDiabetes Mellitus, Type 2FemaleHumansHypoglycemic AgentsMaleMetforminPatient Education as TopicTreatment OutcomeUnited StatesConceptsType 2 diabetesDiabetes educationGlycemic controlRecent-onset type 2 diabetesLow-density lipoprotein cholesterolBiochemical parametersCardiometabolic risk factorsDiagnosis of T2DBody mass indexShort-term improvementStandardized diabetes educationInsulin discontinuationTarget HbA1cCommon comorbiditiesInsulin therapyLipoprotein cholesterolMedian hemoglobinBlood pressureMedian ageT2D cohortMass indexTreatment optionsRisk factorsEarly treatmentOutcome measures
2014
Contrasting the clinical care and outcomes of 2,622 children with type 1 diabetes less than 6 years of age in the United States T1D Exchange and German/Austrian DPV registries
Maahs DM, Hermann JM, DuBose SN, Miller KM, Heidtmann B, DiMeglio LA, Rami-Merhar B, Beck RW, Schober E, Tamborlane WV, Kapellen TM, Holl RW, for the DPV Initiative and the T1D Exchange Clinic Network. Contrasting the clinical care and outcomes of 2,622 children with type 1 diabetes less than 6 years of age in the United States T1D Exchange and German/Austrian DPV registries. Diabetologia 2014, 57: 1578-1585. PMID: 24893863, DOI: 10.1007/s00125-014-3272-2.Peer-Reviewed Original ResearchConceptsType 1 diabetesYounger patientsClinical outcomesT1D ExchangeTreatment modalitiesGerman/Austrian DPV registryAims/hypothesisThe studyFrequency of DKAProspective Diabetes FollowImproved metabolic controlRisk of DKAYears of ageDPV registryRegistry participantsAdolescent DiabetesHypothesisThe studyInjection usersClinical careMetabolic controlFrequency of SHT1DXAge groupsInsulin pumpParticipant characteristicsType 1
2013
Faster In and Faster Out: Accelerating Insulin Absorption and Action by Insulin Infusion Site Warming
Cengiz E, Weinzimer SA, Sherr JL, Tichy EM, Carria L, Cappiello D, Steffen A, Tamborlane WV. Faster In and Faster Out: Accelerating Insulin Absorption and Action by Insulin Infusion Site Warming. Diabetes Technology & Therapeutics 2013, 16: 20-25. PMID: 24367934, PMCID: PMC3887414, DOI: 10.1089/dia.2013.0187.Peer-Reviewed Original ResearchEffectiveness of Early Intensive Therapy on β-Cell Preservation in Type 1 Diabetes
Buckingham B, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA, Bremer AA, Slover R, Tamborlane WV, . Effectiveness of Early Intensive Therapy on β-Cell Preservation in Type 1 Diabetes. Diabetes Care 2013, 36: 4030-4035. PMID: 24130350, PMCID: PMC3836135, DOI: 10.2337/dc13-1074.Peer-Reviewed Original ResearchConceptsUsual care groupC-peptide concentrationsType 1 diabetesΒ-cell functionHybrid closed-loop controlSAP therapyPump therapyContinuous glucose monitorNew-onset type 1 diabetesPeak C-peptide concentrationMixed-meal tolerance testSensor-augmented pump therapyEarly intensive therapyΒ-cell preservationUsual care participantsDays of diagnosisC-peptide areaMultiple daily injectionsInsulin pump therapyDays/weekMean glucose concentrationMedian durationIntensive therapyPrimary outcomeDaily injections
2012
The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence
Ruedy KJ, Tamborlane WV, for the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence. Journal Of Cardiovascular Translational Research 2012, 5: 380-387. PMID: 22538483, DOI: 10.1007/s12265-012-9364-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBiomarkersBlood GlucoseBlood Glucose Self-MonitoringChildDiabetes Mellitus, Type 1Equipment DesignEvidence-Based MedicineGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsMulticenter Studies as TopicPatient SatisfactionPredictive Value of TestsRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsContinuous glucose monitorRandomized trialsT1D managementMulticenter Randomized TrialType 1 diabetesStandard glucose monitoringPrimary studiesComplications TrialSevere hypoglycemiaHemoglobin levelsDiabetes controlBiochemical hypoglycemiaCGM usePatientsGlucose monitoringAccumulated evidenceSecondary studiesReduced exposureTrialsA1CHypoglycemiaGlucose monitorSubjectsDCCTDiabetes
2011
Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study Results from the 6-month continuation phase
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA, . Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study Results from the 6-month continuation phase. Diabetes Care 2011, 34: 2403-2405. PMID: 21933908, PMCID: PMC3198292, DOI: 10.2337/dc11-1248.Peer-Reviewed Original ResearchEffectiveness of sensor‐augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study
Slover RH, Welsh JB, Criego A, Weinzimer SA, Willi SM, Wood MA, Tamborlane WV. Effectiveness of sensor‐augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatric Diabetes 2011, 13: 6-11. PMID: 21722284, DOI: 10.1111/j.1399-5448.2011.00793.x.Peer-Reviewed Original ResearchConceptsType 1 diabetesSensor-augmented pump therapyA1C valuesSAP groupMDI groupPump therapyA1C targetsSAP therapyHyperglycemic excursionsMultiple daily injection therapyBaseline A1C valuesRisk of hypoglycemiaA1C reductionInjection therapyPediatric patientsGlycemic excursionsGlucose variabilityMDI therapyGlycemic variabilityLower AUC valuesTreatment groupsTherapyCGM studiesDiabetesAUC valuesLong-term Results of an Obesity Program in an Ethnically Diverse Pediatric Population
Savoye M, Nowicka P, Shaw M, Yu S, Dziura J, Chavent G, O'Malley G, Serrecchia JB, Tamborlane WV, Caprio S. Long-term Results of an Obesity Program in an Ethnically Diverse Pediatric Population. Pediatrics 2011, 127: 402-410. PMID: 21300674, PMCID: PMC3065145, DOI: 10.1542/peds.2010-0697.Peer-Reviewed Original ResearchConceptsControl groupLow-density lipoprotein cholesterolTotal body fat massIntensive lifestyle programIntensive lifestyle interventionHomeostasis model assessmentActive intervention phaseWeight management programBody fat massLong-term resultsBMI z-scorePercent body fatDiverse pediatric populationFamily-based programsLifestyle interventionLipoprotein cholesterolTotal cholesterolObese childrenObese populationPediatric populationInsulin resistanceObesity programLifestyle programFat massIntervention group
2010
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. New England Journal Of Medicine 2010, 363: 311-320. PMID: 20587585, DOI: 10.1056/nejmoa1002853.Peer-Reviewed Original ResearchConceptsInjection therapy groupPump-therapy groupSensor-augmented pump therapyGlycated hemoglobin levelsHemoglobin levelsType 1 diabetesPump therapyBaseline glycated hemoglobin levelMultiple daily insulin injectionsType 1 diabetes mellitusGlycated haemoglobin targetPrimary end pointProportion of patientsDaily insulin injectionsSignificant weight gainRecombinant insulin analogueHemoglobin targetsInjection therapyDiabetes mellitusSevere hypoglycemiaInsulin injectionsClinical teamInsulin analoguesEnd pointTherapy
2009
From pumps to prevention: recent advances in the treatment of type 1 diabetes
Sherr J, Cengiz E, Tamborlane WV. From pumps to prevention: recent advances in the treatment of type 1 diabetes. Drug Discovery Today 2009, 14: 973-981. PMID: 19580883, DOI: 10.1016/j.drudis.2009.06.011.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAutoimmunityBiosensing TechniquesBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1Drug Therapy, CombinationGlycated HemoglobinHumansHypoglycemic AgentsImmunologic FactorsInfusion PumpsInsulinInsulin-Secreting CellsPancreas, ArtificialPrimary PreventionTreatment OutcomeConceptsContinuous subcutaneous insulin infusionContinuous glucose monitoringType 1 diabetes mellitusBeta-cell destructionRapid-acting insulinSubcutaneous insulin infusionTreatment of T1DMType 1 diabetesBlood glucose fluctuationsImproved insulin deliveryAutoimmune processDiabetes mellitusPediatric patientsSecondary interventionsTreatment optionsInsulin infusionNew medicationsGlucose fluctuationsGlucose monitoringInsulin deliveryArtificial pancreasPreventionTreatmentInitial studyMellitus
2008
Low‐fat vs. high‐fat bedtime snacks in children and adolescents with type 1 diabetes
Wilson D, Chase HP, Kollman C, Xing D, Caswell K, Tansey M, Fox L, Weinzimer S, Beck R, Ruedy K, Tamborlane W, Group T. Low‐fat vs. high‐fat bedtime snacks in children and adolescents with type 1 diabetes. Pediatric Diabetes 2008, 9: 320-325. PMID: 18768036, PMCID: PMC2593894, DOI: 10.1111/j.1399-5448.2008.00393.x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildChild, PreschoolDiabetes Mellitus, Type 1Dietary FatsFemaleHumansHyperglycemiaHypoglycemiaMaleTreatment Outcome
2007
FreeStyle Navigator Continuous Glucose Monitoring System Use in Children With Type 1 Diabetes Using Glargine-Based Multiple Daily Dose Regimens Results of a pilot trial Diabetes Research in Children Network (DirecNet) Study Group
Weinzimer S, Xing D, Tansey M, Fiallo-Scharer R, Mauras N, Wysocki T, Beck R, Tamborlane W, Ruedy K. FreeStyle Navigator Continuous Glucose Monitoring System Use in Children With Type 1 Diabetes Using Glargine-Based Multiple Daily Dose Regimens Results of a pilot trial Diabetes Research in Children Network (DirecNet) Study Group. Diabetes Care 2007, 31: 525-527. PMID: 18096811, PMCID: PMC2365493, DOI: 10.2337/dc07-1995.Peer-Reviewed Original Research